Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cymabay Therapeutics
(NQ:
CBAY
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cymabay Therapeutics
< Previous
1
2
3
4
Next >
Why CymaBay Therapeutics Stock Is Sinking This Week
September 21, 2023
The stock has given up some of its gains but remains up more than 130% year to date.
Via
The Motley Fool
Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease
September 21, 2023
Thursday, CymaBay Therapeutics Inc (NASDAQ: CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar on clinical outcomes in patients with compensated cirrhosis due...
Via
Benzinga
Why CymaBay Therapeutics Stock Triumphed Again on Tuesday
September 12, 2023
The company is about to reap more money than previously expected from a new capital-raising effort.
Via
The Motley Fool
Why CymaBay Therapeutics Stock Popped Again Today
September 11, 2023
Days after it reported highly encouraging news from a clinical trial, the company announced a new round of capital-raising.
Via
The Motley Fool
Why Hooker Furnishings Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
September 08, 2023
Gainers Biocept, Inc. (NASDAQ: BIOC) shares jumped 97.6% to $1.6608 after the company announced non-exclusive licensing agreement for CNSide with Plus Therapeutics.
Via
Benzinga
Analyst Expectations for CymaBay Therapeutics's Future
August 31, 2023
Via
Benzinga
Why CymaBay Therapeutics Stock Is Jumping Today
September 08, 2023
The momentum continues after CymaBay reported great clinical results on Thursday.
Via
The Motley Fool
Why CymaBay, With 172% Growth This Year, Just Surged For A Second Day Running
September 08, 2023
The company is working on a treatment for a liver disease that can cause severe itching.
Via
Investor's Business Daily
Smartsheet, Kroger, Lantronix And Other Big Stocks Moving Higher On Friday
September 08, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording gains in today’s session. Lantronix, Inc. (NASDAQ: LTRX) shares jumped 26.3% to...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
CymaBay Therapeutics' Lead Drug Candidate Hits Main Goal In Pivotal Study For Liver Damage
September 07, 2023
CymaBay Therapeutics Inc (NASDAQ: CBAY) released topline results from its Phase 3 pivotal RESPONSE study of seladelpar for adult patients with
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
September 07, 2023
Via
Benzinga
CymaBay Therapeutics Inc. (NASDAQ: CBAY) Climbs to New 52-Week High
August 11, 2023
Via
Investor Brand Network
Earnings Preview For CymaBay Therapeutics
August 09, 2023
Via
Benzinga
7 Analysts Have This to Say About CymaBay Therapeutics
July 31, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 14, 2023
August 14, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2023
August 11, 2023
Via
Benzinga
CymaBay Therapeutics Inc. (NASDAQ: CBAY) Leading the Way in Friday Trading Based on Percentage Gain
June 30, 2023
Via
Investor Brand Network
Why Shares of CymaBay Therapeutics Are Soaring Friday
June 30, 2023
A competitor's drug had a so-so phase 3 trial, lifting the possibilities for CymaBay's lead therapy.
Via
The Motley Fool
Analyst Expectations for CymaBay Therapeutics's Future
June 26, 2023
Via
Benzinga
Intercept Pharma Gets Double Upgrade: Analyst Says OCA Combo Therapy Can Extend PBC Business
July 13, 2023
HC Wainwright has upgraded Intercept Pharmaceuticals Inc (NASDAQ: ICPT) to Buy from Sell, with a price target of
Via
Benzinga
Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class
June 30, 2023
Friday, CymaBay Therapeutics Inc's (NASDAQ: CBAY) competitors Genfit SA (NASDAQ: GNFT) and Ipsen SA (OTC:
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
June 30, 2023
Via
Benzinga
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
June 30, 2023
Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top...
Via
Benzinga
Expert Ratings for CymaBay Therapeutics
May 16, 2023
Via
Benzinga
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday
June 30, 2023
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Dow Surges 200 Points; Constellation Brands Posts Upbeat Results
June 30, 2023
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 200 points on Friday. Following the market opening Friday, the Dow traded up 0.63% to 34,338.23 while the NASDAQ rose 1.05%...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
June 30, 2023
Via
Benzinga
Former Wall Street Darling Intercept Restructures After FDA Rejects Its Liver Drug
June 23, 2023
Following the FDA rejection, Intercept will restructure to focus on rare liver diseases.
Via
Investor's Business Daily
What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur
May 22, 2023
On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's ICPT Ocaliva 25 mg, also known as Obeticholic acid...
Via
Benzinga
Why CymaBay Therapeutics Stock Nose-Dived This Week
May 19, 2023
Investors did not warmly greet the latest news from the biotech.
Via
The Motley Fool
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.